Ganitumab for the treatment of small-cell lung cancer, PMID: 25189625
Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy, PMID: 24727326
Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy, PMID: 28427155
A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer, PMID: 29572245
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial, PMID: 23414585
IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice, PMID: 24492468
Epitope-specific mechanisms of IGF1R inhibition by ganitumab, PMID: 23383308
Differential Pharmacokinetics of Ganitumab in Patients With Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers, PMID: 27121941
Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models, PMID: 21385891
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors, PMID: 22510349
Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts, PMID: 23348048
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors, PMID: 22810805
Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors, PMID: 22508822
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial, PMID: 25609246
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer, PMID: 28601388
Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study, PMID: 24782485
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer, PMID: 24919569
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer, PMID: 22700995
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors, PMID: 23572164
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab, PMID: 24816908
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor, PMID: 23741071
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer, PMID: 23510984
A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells, PMID: 25344862
Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts, PMID: 23823800
Recent advances in targeted therapy for Ewing sarcoma, PMID: 27635231
Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review, PMID: 32770529
Minireview: Were the IGF Signaling Inhibitors All Bad?, PMID: 26366975
Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade, PMID: 26429980
The impact of timing of EGFR and IGF-1R inhibition for sensitizing head and neck cancer to radiation, PMID: 22843870
Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials, PMID: 28256961
Insulin-like growth factor receptor inhibitors: baby or the bathwater?, PMID: 22761272
Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts, PMID: 22562985
Flagellate Dermatitis in a Child Most Likely Secondary to Doxorubicin, PMID: 28804924
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer, PMID: 29123263
Anticancer IGF1R classes take more knocks, PMID: 23535923
IGF-1R inhibition: right direction, wrong pathway?, PMID: 23414584
Therapy: Blockade of IGF-1R-not effective in neuroendocrine tumours, PMID: 23732282
A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer, PMID: 27806321
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer, PMID: 22678353
Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers, PMID: 23051797
AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways, PMID: 21846689
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma, PMID: 20652976
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1, PMID: 19786654
AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells, PMID: 19366899
For research use only. Not for human or drug use.
